医药生物行业双周报：AI赋能将逐步深化，关注前端药物研发和后端病理诊断等应用领域

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index increased by 6.02%, ranking 6th among 31 primary industries, outperforming the CSI 300 index which rose by 3.19% [3][10] - The PE ratio (TTM, excluding negative values) for the industry as of February 14, 2025, is 26.68x, up from 25.41x in the previous period, indicating an upward valuation trend but still below the average [12] - The AI healthcare market in China is projected to grow significantly, with an expected increase from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, reflecting a compound annual growth rate of 43.1% [5] Industry Review - The top-performing sub-industries during the reporting period were hospitals and medical devices, with increases of 14.31% and 12.54% respectively, while blood products and chemical preparations lagged behind with increases of 0.57% and 2.38% [3][10] - A total of 249 out of 501 tracked pharmaceutical and biotechnology companies disclosed their 2024 performance forecasts, with 43 companies expecting significant profit increases of 30% or more [4] Important Industry News - The National Healthcare Security Administration released a list of key tasks for 2025 aimed at improving efficiency in medical insurance and drug procurement [15] - The approval of the first domestic biosimilar drug, "Westuximab," by Kelun Biotech marks a significant milestone in the industry [22] - The acquisition of a 28% stake in Tian Shi Li by China Resources Sanjiu for approximately 6.2 billion yuan is expected to enhance market competitiveness and resource integration [38][40]